Customer HesitancyBiopharma customers have become more hesitant to make capital purchases of its systems, and this trend intensified.
Market PressureShares are down 34% year-to-date reflecting broader market pressure on longer-duration assets, macro uncertainty, and its possible impact on MaxCyte’s customers.
Revenue Growth ConcernsThe 2025 revenue guide was lower than expected, particularly for core organic growth.